Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2018

View Archived Issues

Uncovering the regulatory role of a prognostic microRNA in pancreatic ductal adenocarcinoma

Study finds nitrated meat products are associated with mania-like hyperactivity

Angiotensin II activates a macrophage-to-sensory neuron crosstalk in peripheral pain sensitization

One protein affects translation of multiple autism risk genes

GNE-684: a potent inhibitor of RIPK1 for treating inflammatory diseases due to dysregulated NEMO

Viela Bio initiates first-in-human study of VIB-9600

Amgen initiates first-in-human studies with AMG-424 and AMG-397

Ichor announces utilization of TriGrid delivery system in a phase I/IIb study of GX-188E vaccine

ProMIS Neurosciences reports positive results for PMN-310 in Alzheimer's disease

GNE-616: a promising non-opioid drug candidate for the treatment of Nav1.7-mediated pain

Lixte partners with Moffitt for phase Ib/II study of LB-100 in low and intermediate-1 risk MDS

Boehringer Ingelheim discovers new FFAR1 agonists

At ACS national meeting, researchers share their successes

Sihuan initiates phase II trial with anaprazole in China

New LRRK2 inhibitors patented by GlaxoSmithKline

UCB presents alpha-synuclein aggregation inhibitors

Sun Pharma Advanced Research Co. identifies estrogen receptor antagonists

Araxes Pharma patents KRAS inhibitors

Ono announces new Japanese approvals for Opdivo

Hanmi Science synthesizes new protein kinase inhibitors

Biosceptre initiates phase I trial with peptide cancer vaccine BIL-06v

Berlin Cures completes phase I study of BC-007 for cardiomyopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...